I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NXi0RpFH[3m2b4TvfIlkcXS7IHHzd4F6 MWP+NVAxKM7:TR?= M3;aUWROW09? NFnLOmpKSzVyPUK2JI5O M3rtVlIyQTZ2M{Sw
RS4;11 NVKzbm9C[3m2b4TvfIlkcXS7IHHzd4F6 NVzYc3NohjFyMDFOwG0> NXr4e4lHTE2VTx?= M{K0VGlEPTB;MUmyJI5O MlW4NlE6PjR|NEC=
MOLM13 M{LJVYN6fG:2b4jpZ4l1gSCjc4PhfS=> NXToW5ZphjFyMDFOwG0> M2\SUGROW09? MYnJR|UxRTF{MDDuUS=> MlHtNlE6PjR|NEC=
NOMO1 NYXGUZdv[3m2b4TvfIlkcXS7IHHzd4F6 NFTvboF,OTByIN88US=> MlfrSG1UVw>? MmHKTWM2OD1zNTDuUS=> MmjBNlE6PjR|NEC=
HEL MkC5Z5l1d3SxeHnjbZR6KGG|c3H5 NGnMemt,OTByIN88US=> NUDTO4VKTE2VTx?= MoLzTWM2OD1zIN88US=> NYTITJFNOjF7NkSzOFA>
K562 Mlm4Z5l1d3SxeHnjbZR6KGG|c3H5 NFflOHV,OTByIN88US=> M4\WdGROW09? MXfJR|UxRjFyMDFOwG0> NFfVbmYzOTl4NEO0NC=>
MEG01 MkPlZ5l1d3SxeHnjbZR6KGG|c3H5 M{n3OJ4yODBizszN NEHvRndFVVOR NUPrUHZFUUN3ME2yOUDPxE1? NXz5bHFQOjF7NkSzOFA>
HL60 M2nnRoN6fG:2b4jpZ4l1gSCjc4PhfS=> NImyO2l,OTByIN88US=> NEH1fHVFVVOR NYH5NJNTUUN3ME24PVAhdk1? M1PJO|IyQTZ2M{Sw
MV4;11 M13ZbmFxd3C2b4Ppd{Bie3OjeR?= MV7+NVAxKM7:TR?= NX3YXFZLTE2VTx?= NXXYfFZ{cW6mdXPld{BieG:ydH;zbZM> M13JelIyQTZ2M{Sw
MOLM13 MV\BdI9xfG:|aYOgZZN{[Xl? MU\+NVAxKM7:TR?= Ml3rSG1UVw>? MkXjbY5lfWOnczDhdI9xfG:|aYO= MYqyNVk3PDN2MB?=
MV4;11 NFXTS5JHfW6ldHnvckBie3OjeR?= MmWxSG1UVw>? MmDv[IVkemWjc3XzJJRp\SC{ZXPyeYl1dWWwdDDv[kBDWkR|L{SgZY5lKGmvcHHpdoVlKHKnY4L1bZRu\W62IH;mJGNFUzliYX7kJHBCTjFidH:geIhmKHS{YX7zZ5JqeHSrb37hcEB{fGG{dDDzbZRm NWnZfWFUOjF7NkSzOFA>
PBMC MYrGeY5kfGmxbjDhd5NigQ>? NIPNSnhFVVOR M1[xeIlvcGmkaYTzJGlNNTZid3n0bEBxUUN3MDDv[kA3Njd? M3;ue|IzPDN5MUG1
A2 MnrSSpVv[3Srb36gZZN{[Xl? M{LmXJ4yOCEQvF2= M134VWROW09? NELwdFNz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= NHT6XIszOzJ3NUKxPC=>
A72 MnPISpVv[3Srb36gZZN{[Xl? MUT+NVAh|ryP NIXRV3lFVVOR NG\meWlz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= Mo\pNlMzPTV{MUi=
BC1 NWXzfIJrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NE[xTmJ,OSEQvF2= MUHEUXNQ MXzJR|UxRTJ{MDDuUS=> MYCyN|c6OjR2OB?=
BC3 MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{j4T54yKM7:TR?= M4rHdWROW09? Mo[2TWM2OD12NkCgcm0> NGrJZpczOzd7MkS0PC=>
BCBL1 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYL0OZJNhjFizszN NX7IcmRRTE2VTx?= M1vCRWlEPTB;M{OwJI5O MnTuNlM4QTJ2NEi=
BJAB Mk\xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVP+NUDPxE1? MoLZSG1UVw>? MoCxTWM2OD17N{Cgcm0> M1;oOlI{Pzl{NES4
Namalwa MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX3+NUDPxE1? NX\4eGUxTE2VTx?= NHzVPVlKSzVyPUm3NEBvVQ>? Mo\VNlM4QTJ2NEi=
Jurkat NUHHR4lnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2m1Zp4yKM7:TR?= MYXEUXNQ MlKyTWM2OD1zMkKwJI5O NFLpXoYzOzd7MkS0PC=>
MM1S M2HBVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWrEUFlnhjFizszN MnLZSG1UVw>? Ml3RTWM2OD15NkCgcm0> M1;JclI{Pzl{NES4
U266 MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MorHglEh|ryP M{XuRmROW09? NVqyNZhsUUN3ME25OVAhdk1? MmrGNlM4QTJ2NEi=
UM-PEL-1 NI\Ic2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoLuglEh|ryP NHTpc2RFVVOR MXnJR|UxRTJzMDDuUS=> MVeyN|c6OjR2OB?=
UM-PEL-3 M{\MO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXHjbXFUhjFizszN NWX3dGZYTE2VTx?= MYLJR|UxRTF6MDDuUS=> NYr2dWlIOjN5OUK0OFg>
BC1 NXr6TWdjTnWwY4Tpc44h[XO|YYm= NWjWUG9wPTByIH7N MlTwSG1UVw>? NIfJOGFqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MnrCNlM4QTJ2NEi=
BC3 M{HHW2Z2dmO2aX;uJIF{e2G7 NF\ERnU2ODBibl2= M3nRSGROW09? MYDpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 MXiyN|c6OjR2OB?=
BC1 NHK2WGFHfW6ldHnvckBie3OjeR?= NUHBOoQyQDByIH7N M1;4dmROW09? NWLKVFU2emWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? NG\IS4ozOzd7MkS0PC=>
BC3 NFHNSllHfW6ldHnvckBie3OjeR?= MkjUPFAxKG6P NWLoO5J7TE2VTx?= NHvObJpz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ M2\GclI{Pzl{NES4
H929 NYn5[YpKTnWwY4Tpc44h[XO|YYm= NYntemtOhjFizszN NYn1SG1ZTE2VTx?= Ml7ZbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NIDSTmYzPDN|NUS5PS=>
KMS12PE NWSxN|hsTnWwY4Tpc44h[XO|YYm= M{O3c54yKM7:TR?= NVHXNWZITE2VTx?= Mn3sbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MkHoNlQ{OzV2OUm=
KMS12BM NGj6OWdHfW6ldHnvckBie3OjeR?= MoLsglEh|ryP NVnhNIVLTE2VTx?= M1;NUIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NVTHTlNxOjR|M{W0PVk>
KMS18 MnHSSpVv[3Srb36gZZN{[Xl? Ml[3glEh|ryP NXvnXoRpTE2VTx?= MVHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M3[wOlI1OzN3NEm5
KMS11 NVjweGhFTnWwY4Tpc44h[XO|YYm= M1fxe54yKM7:TR?= Mn3LSG1UVw>? NXvE[29NcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> Mkn5NlQ{OzV2OUm=
RPMI8226 MVnGeY5kfGmxbjDhd5NigQ>? NH\TZmF,OSEQvF2= MXPEUXNQ NV;ObmdkcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NWKxblRJOjR|M{W0PVk>
H929 MnH6RZBweHSxc3nzJIF{e2G7 MnHHglEh|ryP MnW3SG1UVw>? Ml;wbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{Hyb|I1OzN3NEm5
KMS12PE MmjwRZBweHSxc3nzJIF{e2G7 Mk[1glEh|ryP M{iwVmROW09? NGfCV29qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmTFNlQ{OzV2OUm=
KMS12BM Mlu0RZBweHSxc3nzJIF{e2G7 MnfuglEh|ryP MVTEUXNQ NILyU5JqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mm\5NlQ{OzV2OUm=
KMS18 NEeyV2dCeG:ydH;zbZMh[XO|YYm= MXf+NUDPxE1? M3vqWGROW09? NW\xU|l3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MljQNlQ{OzV2OUm=
KMS11 MYjBdI9xfG:|aYOgZZN{[Xl? MVL+NUDPxE1? MWLEUXNQ NG\pR3pqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NILVO3gzPDN|NUS5PS=>
RPMI8226 NGrMUGxCeG:ydH;zbZMh[XO|YYm= M3L3Np4yKM7:TR?= M2TvN2ROW09? NELCeppqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NInlOXUzPDN|NUS5PS=>
U87MG MWHGeY5kfGmxbjDhd5NigQ>? NXn5WJlyhjFyIN88US=> M2fI[WROW09? NFixTmZz\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1? NUH1XYxYOjR2OU[zPFE>
A172 NYrUV|dQTnWwY4Tpc44h[XO|YYm= NU\JT5lKhjFyIN88US=> NW\2eWNOTE2VTx?= NWrVSnJGemWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFEvOjhizszN NHvTe|czPDR7NkO4NS=>
SW1783 MUnGeY5kfGmxbjDhd5NigQ>? MU\+NVAh|ryP MVjEUXNQ MlrHdoVlfWOnczDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEKuOlgh|ryP MoGyNlQ1QTZ|OEG=
U87MG M4\5NGZ2dmO2aX;uJIF{e2G7 MYr+NVAh|ryP NUHOPJJ4TE2VTx?= M3i4PIlv[3KnYYPld{Bxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOS:VIITyZY5{cXSrb36= MYGyOFQ6PjN6MR?=
RAW267.4 NGS0UVVHfW6ldHnvckBie3OjeR?= M4W0[VEh|ryP MX7EUXNQ MkHPdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> MkLDNlQ5PTlyMEi=
RAW267.4 MnL3SpVv[3Srb36gZZN{[Xl? M{LqPVEh|ryP M33tSWROW09? NV;tUpJ4emWmdXPld{B1cGViYYPzc4Nq[XSrb36gZoV1f2WnbjDCVmQ1KGGwZDDhZ4V1gWyjdHXkJJA3PQ>? M2m3UVI1QDV7MEC4
Me007 NYfKSW85T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWf+NVAxKM7:TR?= MleySG1UVw>? MXfpcohq[mm2czD0bIUh\3Kxd4To NEm0V4UzPDlyNkGzOy=>
SK-Mel-28 M3PHWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXP+NVAxKM7:TR?= NXfXW|A6TE2VTx?= MXPpcohq[mm2czD0bIUh\3Kxd4To M{SxVFI1QTB4MUO3
Mel-RMU MlPKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3PYPJ4yODBizszN MXXEUXNQ MkOxbY5pcWKrdIOgeIhmKGe{b4f0bC=> MUiyOFkxPjF|Nx?=
Mel-JD NUHNVYtpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVP0bmZihjFyMDFOwG0> NHP0[|BFVVOR NF63PVhqdmirYnn0d{B1cGViZ4Lve5Rp MVmyOFkxPjF|Nx?=
Mel-RM M4DSWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlrOglExOCEQvF2= NEHlOHJFVVOR M3nISYlvcGmkaYTzJJRp\SCpcn;3eIg> MXuyOFkxPjF|Nx?=
Me007 NXv0cHM1SXCxcITvd4l{KGG|c3H5 MUX+NVAxKM7:TR?= NFLZS5ZFVVOR NWL5PWpHcW6mdXPld{BieG:ydH;zbZM> NYnyRWtkOjR7ME[xN|c>
SK-Mel-28 M2rkdGFxd3C2b4Ppd{Bie3OjeR?= M{XEPJ4yODBizszN M1;JS2ROW09? NEP5[2lqdmS3Y3XzJIFxd3C2b4Ppdy=> MomyNlQ6ODZzM{e=
Mel-RMU MljTRZBweHSxc3nzJIF{e2G7 NEj5TYR,OTByIN88US=> NELRZlVFVVOR NWnjWpZ5cW6mdXPld{BieG:ydH;zbZM> M3zDZVI1QTB4MUO3
Mel-JD NHHJS4NCeG:ydH;zbZMh[XO|YYm= NUTlNWxHhjFyMDFOwG0> NYflS3B3TE2VTx?= MnvpbY5lfWOnczDhdI9xfG:|aYO= Mn\yNlQ6ODZzM{e=
Mel-RM Mn3qRZBweHSxc3nzJIF{e2G7 NUm5XXc1hjFyMDFOwG0> MkLPSG1UVw>? NWWwOXlHcW6mdXPld{BieG:ydH;zbZM> NUTL[nZ[OjR7ME[xN|c>
Me007 NXfSbFFOTnWwY4Tpc44h[XO|YYm= MXqxNEDPxE1? NFexbW9FVVOR NGPBVHBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NGS5NHUzPDlyNkGzOy=>
SK-Mel-28 NW[yVod6TnWwY4Tpc44h[XO|YYm= NFezUYEyOCEQvF2= NILmZpFFVVOR MYLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NGPMNY4zPDlyNkGzOy=>
Mel-RMU NHjvbYJHfW6ldHnvckBie3OjeR?= NXy5cnMyOTBizszN NHrJT4tFVVOR M2iyPIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NXj4cmxSOjR7ME[xN|c>
Mel-JD NUS1VJFnTnWwY4Tpc44h[XO|YYm= M1i2VFExKM7:TR?= MWDEUXNQ MVTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MoDpNlQ6ODZzM{e=
Mel-RM NHLxXW1HfW6ldHnvckBie3OjeR?= NFrlSlgyOCEQvF2= MX3EUXNQ MorwbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy M4DrU|I1QTB4MUO3
Me007 MVzGeY5kfGmxbjDhd5NigQ>? MXixNEDPxE1? NWHt[GV3TE2VTx?= MVX1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| M2rMVlI1QTB4MUO3
SK-Mel-28 NVTWd2p1TnWwY4Tpc44h[XO|YYm= M4PCTlExKM7:TR?= NHmzW3dFVVOR NFzEdpN2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz Mn\FNlQ6ODZzM{e=
Mel-RMU NIHDOlRHfW6ldHnvckBie3OjeR?= M17tXFExKM7:TR?= NFrhTnNFVVOR MUX1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| MYeyOFkxPjF|Nx?=
Mel-JD NUnteWF1TnWwY4Tpc44h[XO|YYm= M{nkSlExKM7:TR?= NVT0bZVKTE2VTx?= M4O2NZVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NXTFbGFDOjR7ME[xN|c>
Mel-RM MV7GeY5kfGmxbjDhd5NigQ>? MVuxNEDPxE1? MWTEUXNQ NIi1eox2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz MVqyOFkxPjF|Nx?=

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID